Endonovo Therapeutics, Inc. is a development-stage biotechnology company focused on the research, development and commercialization of bioelectronic medicine and regenerative therapies for chronic and acute health conditions. The company’s core business activities center on the design and manufacturing of pulsed electromagnetic field (PEMF) devices that target cellular repair and anti-inflammatory pathways, as well as the development of stem cell and exosome-based platforms intended to support tissue regeneration.
The company offers a portfolio of medical-grade devices, including wearable and clinic-based PEMF systems, which are designed to modulate cellular signaling and promote healing in areas such as musculoskeletal injuries, neuropathic pain and post-operative rehabilitation. In parallel, Endonovo is advancing a pipeline of biologic candidates, with early-stage programs exploring the therapeutic potential of mesenchymal stem cell exosomes to address cardiovascular, pulmonary and immunological disorders.
Originally founded to drive innovation at the intersection of electronics and life sciences, Endonovo has completed multiple preclinical studies to validate its energy-delivery technology and has initiated regulatory pathways in key markets. The company’s products and research collaborations span North America, Latin America and select European territories, with distribution partners in clinical research centers, physical therapy networks and specialty clinics.
Endonovo’s executive leadership team is led by a seasoned president and chief executive officer supported by experts in biomedical engineering, regulatory affairs and finance. Guided by a board of directors with deep experience in life sciences commercialization and corporate governance, the company continues to refine its technologies and expand strategic partnerships aimed at delivering novel treatment options to healthcare providers and patients worldwide.
AI Generated. May Contain Errors.
